Page 5,147«..1020..5,1465,1475,1485,149..5,1605,170..»

Stemedica Enters into a Global Distribution Agreement with Life Technologies

Posted: Published on June 14th, 2013

San Diego, CA (PRWEB) June 13, 2013 Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedicas ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally. Stemedica stem cell lines will be sold under the brand name Gibco and will be available to purchase for research initiatives beginning Q2, 2013. The label will also carry the name of Stemedica as the manufacturer of the cell lines. Life Technologies is a global biotechnology company with customers in more than 180 countries, providing more than 50,000 end-to-end solutions for customers in the fields of scientific research, genetic analysis and applied sciences. The Companys systems, reagents and consumables represent some of the most cited brands in scientific research. Life Technologies employs approximately 10,000 people and upholds its ongoing commitment to innovation with more than 5,000 patents and exclusive licenses. The Company had sales of $3.8 billion in 2012. We are honored … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Stemedica Enters into a Global Distribution Agreement with Life Technologies

Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-6063 in Mesothelioma

Posted: Published on June 14th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases. We are pleased that the EMA recognizes the significant unmet medical need in mesothelioma, said Christoph Westphal, M.D., Ph.D., Verastem Chairman and Chief Executive Officer. This orphan drug designation provides us with a number of benefits in the development of VS-6063. VS-6063 is an orally-available, small molecule inhibitor of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed a critical role for cancer stem cell survival and disease progression. Mesothelioma is a devastating disease with limited treatment options, said Dr. Joanna Horobin, Verastem Chief Medical Officer. We are working with investigators throughout Europe and internationally to bring a new treatment option for these patients. A biomarker test is being developed in conjunction with LabCorp (LH) to identify a subgroup of mesothelioma patients low in a marker called Merlin. Approximately 40-50% of mesothelioma patients lack Merlin. Studies by … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-6063 in Mesothelioma

Mount Sinai Researchers Succeed in Programming Blood Forming Stem Cells

Posted: Published on June 14th, 2013

New York, NY (PRWEB) June 13, 2013 By transferring four genes into mouse fibroblast cells, researchers at the Icahn School of Medicine at Mount Sinai have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. These findings provide a platform for future development of patient-specific stem/progenitor cells, and more differentiated blood products, for cell-replacement therapy. The study, titled, Induction of a Hemogenic Program in Mouse Fibroblasts, was published online in CELL STEM CELL on June 13. Mount Sinai researchers screened a panel of 18 genetic factors for inducing blood-forming activity and identified a combination of four transcription factors, Gata2, Gfi1b, cFos, and Etv6 as sufficient to generate blood vessel precursor cells with the subsequent appearance of hematopoietic cells. The precursor cells express a human CD34 reporter, Sca1 and Prominin1 within a global endothelial transcription program. The cells that we grew in a petri dish are identical in gene expression to those found in the mouse embryo and could eventually generate colonies of mature blood cells, said the first author of the study, Carlos Filipe Pereira, PhD, Postdoctoral Fellow of Developmental and Regenerative Biology at the Icahn School of Medicine. … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Mount Sinai Researchers Succeed in Programming Blood Forming Stem Cells

Scientists challenge patent ban for embryonic stem cell research

Posted: Published on June 14th, 2013

Scientists and lawyers in Britain are challenging a European ban on the patenting of embryonic stem cells which they believe is blocking the development of new treatments for a range of illnesses including diabetes, heart disease and Parkinsons. They have been joined by a High Court judge who has asked the Court of Justice of the European Union in Luxembourg to clarify its decision to prevent the patenting of stem cell research involving the use and destruction of human embryos. Medical researchers and biotechnology firms are incensed by the European courts ban on stem cell patents. They say it is deterring investment in Europe while scientists in Asia forge ahead with research into new medical treatments based on embryonic stem cells. Sir Ian Wilmut, who cloned Dolly the sheep, and Professor Austin Smith of the Wellcome Trust Centre for Stem Cell Research at Cambridge University, said that banning patents has effectively removed the protection of intellectual property that is crucial for commercial investment. Their concerns have now been voiced by Henry Carr QC, a deputy judge of the High Court, who questioned whether the European court really understood the scientific basis of its ban, which it issued last year. The … Continue reading →

Comments Off on Scientists challenge patent ban for embryonic stem cell research

Induced Pluripotent Stem Cell Industry (iPSC Market) Report Updated for 2013 Now Available at ReportsnReports.com

Posted: Published on June 14th, 2013

Dallas, Texas (PRWEB) June 13, 2013 Sales (number) of iPSC research products worldwide have been growing at a rate of 14.7% per year for the past five years. In addition, 22% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community. A distinctive feature of this report is an end-user survey of 293 researchers (181 U.S. / 112 International) that identify as having induced pluripotent stem cells as their core research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. They can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates. Complete 2012-13 Induced Pluripotent Stem Cell Industry Report on market metrics, dynamics, and trends says continued research and experimentation has resulted in numerous advances over the last few years. In one example, the University of Michigan announced in Circulation Research (2012) that they had developed innovative methods for use of induced pluripotent stem cells derived from skin biopsies to create cardiac muscle cells. This accomplishment quickly fueled other research into … Continue reading →

Comments Off on Induced Pluripotent Stem Cell Industry (iPSC Market) Report Updated for 2013 Now Available at ReportsnReports.com

IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology

Posted: Published on June 14th, 2013

NEW YORK, June 13, 2013 /PRNewswire/ --IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm IntelliCell's Chairman and CEO, Dr.Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent, our technology is now protected and we expect our international patent publication in a short time." About IntelliCell BioSciences, Inc. IntelliCellBioSciencesis a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including the … Continue reading →

Comments Off on IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology

Fat Cells Lending to New Treatments in Brain Cancer

Posted: Published on June 14th, 2013

Regenerative medicines hold incredible potential for new, more potent therapeutics to arrive in the future for a broad spectrum of diseases and conditions. As the industry in general is growing, more possibilities are emerging seemingly on a daily basis as research uncovers new ways to use stem cells to potentially combat deadly diseases like cancer where many patients have little to no hope with todays standards of care. A recent blog post on the website of American CryoStem, Corp. (OTCQB:CRYO - News) provides some clear information on the MGMT gene and its role in stunting the effectiveness of treating patients with brain cancer, a disease that kills nearly 14,000 people annually. According to the article, research has shown the powerful role that bone marrow stem cells can play as a combination therapy to increase the efficacy and lower toxicity in MGMT-positive brain cancer patients. However, collecting stem cells from bone marrow is a costly and highly invasive process. New research is outlining the potency of mesenchymal stem cells that are derived from the patients own adipose (fat) tissue that can potentially play a major role in new brain cancer treatments. Doctors arent sure why at this point, but mesenchymal stem … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Fat Cells Lending to New Treatments in Brain Cancer

New molecular-level understanding of the brain's recovery after stroke

Posted: Published on June 14th, 2013

June 13, 2013 A specific MicroRNA, a short set of RNA (ribonuclease) sequences, naturally packaged into minute (50 nanometers) lipid containers called exosomes, are released by stem cells after a stroke and contribute to better neurological recovery according to a new animal study by Henry Ford Hospital researchers. The important role of a specific microRNA transferred from stem cells to brain cells via the exosomes to enhance functional recovery after a stroke was shown in lab rats. This study provides fundamental new insight into how stem cells affect injured tissue and also offers hope for developing novel treatments for stroke and neurological diseases, the leading cause of long-term disability in adult humans. The study is being published in the journal Stem Cells. Although most stroke victims recover some ability to voluntarily use their hands and other body parts, nearly half are left with weakness on one side of their body, while a substantial number are permanently disabled. Currently no treatment exists for improving or restoring this lost motor function in stroke patients, mainly because of mysteries about how the brain and nerves repair themselves. "This study may have solved one of those mysteries by showing how certain stem cells play … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on New molecular-level understanding of the brain's recovery after stroke

Researchers gain new molecular-level understanding of the brain's recovery after stroke

Posted: Published on June 14th, 2013

Public release date: 13-Jun-2013 [ | E-mail | Share ] Contact: Dwight Angell dwight.angell@hfhs.org 313-850-3471 Henry Ford Health System DETROIT A specific MicroRNA, a short set of RNA (ribonuclease) sequences, naturally packaged into minute (50 nanometers) lipid containers called exosomes, are released by stem cells after a stroke and contribute to better neurological recovery according to a new animal study by Henry Ford Hospital researchers. The important role of a specific microRNA transferred from stem cells to brain cells via the exosomes to enhance functional recovery after a stroke was shown in lab rats. This study provides fundamental new insight into how stem cells affect injured tissue and also offers hope for developing novel treatments for stroke and neurological diseases, the leading cause of long-term disability in adult humans. The study, to be published in the journal Stem Cells, is available at http://www.ncbi.nlm.nih.gov/pubmed/23630198. Although most stroke victims recover some ability to voluntarily use their hands and other body parts, nearly half are left with weakness on one side of their body, while a substantial number are permanently disabled. Currently no treatment exists for improving or restoring this lost motor function in stroke patients, mainly because of mysteries about how the … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Researchers gain new molecular-level understanding of the brain's recovery after stroke

Metabolic molecule drives growth of aggressive brain cancer

Posted: Published on June 14th, 2013

Public release date: 13-Jun-2013 [ | E-mail | Share ] Contact: Darrell E. Ward Darrell.Ward@osumc.edu 614-293-3737 Ohio State University Medical Center COLUMBUS, Ohio A study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) has identified an abnormal metabolic pathway that drives cancer-cell growth in a particular glioblastoma subtype. The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer. The physician scientists sought to identify glioblastoma subtype-specific cancer stem cells. Genetic analyses have shown that high-grade gliomas can be divided into four subtypes: proneural, neural, classic and mesenchymal. This study shows that the mesenchymal subtype is the most aggressive subtype, that it has the poorest prognosis among affected patients, and that cancer stem cells isolated from the mesenchymal subtype have significantly higher levels of the enzyme ALDH1A3 compared with the proneural subtype. The findings, published recently in the Proceedings of the National Academy of Sciences, show that high levels of the enzyme drive tumor growth. "Our study suggests that ALDH1A3 is a potentially functional biomarker for mesenchymal glioma stem cells, and that … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Metabolic molecule drives growth of aggressive brain cancer

Page 5,147«..1020..5,1465,1475,1485,149..5,1605,170..»